Heron Therapeutics is trading 5.92% lower at $0.33, with no clear catalyst identified.
- No new company announcement was listed on its investor-relations news page for October 21, so available evidence does not point to a fresh company-specific catalyst.
- XBI was roughly flat early October 21 after a strong prior session, rather than showing a clear same-direction decline. The reason for the drop remains unclear.